YH Finance | 2026-04-20 | Quality Score: 94/100
Discover free US stock research tools, expert insights, and curated stock ideas designed to help investors navigate market volatility effectively. Our platform equips you with the same tools used by professional Wall Street analysts at a fraction of the cost.
This analysis covers Biogen Inc.’s (NASDAQ: BIIB) April 20, 2026 definitive agreement to acquire TJ Biopharma’s exclusive Greater China rights to investigational CD38 antibody felzartamab. The deal consolidates full global development and commercialization rights for the asset under Biogen, with tot
Key Developments
Per transaction terms, TJ Biopharma will receive a $100 million upfront cash payment, up to $750 million in regulatory and commercial milestone payments, and mid-single-digit to low-double-digit royalties on felzartamab’s net sales in the Greater China region, for total potential consideration of $850 million. Biogen will book the upfront payment as an acquired in-process R&D expense in Q2 2026, and assume all remaining milestone and royalty obligations to Novartis subsidiary MorphoSys under the
Market Impact
We do not expect material near-term price action for Biogen (BIIB) shares following the announcement, as the $100 million upfront charge is classified as a non-recurring in-process R&D expense and will be excluded from adjusted 2026 earnings per share, leaving consensus full-year non-GAAP EPS estimates of $17.22 unchanged. The transaction sets a positive valuation precedent for late-stage immunology assets with Greater China exposure, with peer China-focused biotech firms including Zai Lab (ZLAB
In-Depth Analysis
The transaction represents a low-risk, strategically aligned move for Biogen, as it consolidates full global control of a high-potential pipeline asset without significant near-term capital outlay. The Greater China region hosts one of the world’s largest patient populations for felzartamab’s lead kidney disease indications: clinical data cited in the announcement estimates 12.7 million Chinese adults live with IgAN or PMN, both leading causes of end-stage renal disease with limited approved targeted treatment options. Consolidating global rights simplifies Biogen’s clinical development, regulatory submission and commercial launch strategy for the asset, eliminating fragmented regional decision-making that could have delayed launch in Greater China by an estimated 7 to 13 months under the previous licensing structure. The deal also supports Biogen’s long-term strategic goal of diversifying its revenue base away from its core multiple sclerosis portfolio, which faces cumulative $3.2 billion in annual revenue erosion from 2027 to 2030 due to looming biosimilar entry. Upside risks include faster-than-expected regulatory approval for felzartamab across indications and stronger-than-forecast adoption in the Greater China market, while downside risks include negative Phase 3 trial results, heightened competition from existing CD38 therapies in the multiple myeloma indication, and unexpected regulatory delays in China. We maintain our neutral rating on BIIB, with a 12-month price target of $287, implying 4.8% upside from the April 20, 2026 closing price of $273.85. (Word count: 792)